A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)
A Multicenter, Randomized, Double-blind, Parallel, Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10326
- Donggguk University Ilsan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions
- mean sitSBP <180 mmHg and mean sitDBP < 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1
- 140 mmHg ≤ mean sitSBP < 180 mmHg and mean sitDBP < 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1
- Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP < 180 mmHg and mean sitDBP < 110 mmHg at Visit 2
Exclusion Criteria:
- Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
- Orthostatic hypotension with symptoms within 3 months prior to visit 1.
- Secondary hypertensive patient or suspected to be
- Uncontrolled diabetes mellitus(HbA1c > 9%) or type I diabetes mellitus
- Active gout or hyperuricemia (uric acid ≥ 9mg/dL)
- Severe heart disease or severe neurovascular disease
- Moderate or malignant retinopathy
- Clinically significant hematological finding
- Severe renal diseases (eGFR<30mL/min/1.73m2)
- Severe or active hepatopathy (AST or ALT ≥ 3 times of normal range)
- Hypokalemia or Hyperkalemia(K<3.5mmol/L or K ≥ 5.5mmol/L)
- Hyponatremia or Hypernatremia(Na<135mmol/L or Na ≥ 155mmol/L)
- Hypercalcemia
- History of malignancy tumor
- History of autoimmune disease
- History of alcohol or drug abuse
- Positive to pregnancy test, nursing mother, intention on pregnancy
- Considered by investigator as not appropriate to participate in the clinical study with other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental 1
HCP1803-3
|
Take it once daily for 8 weeks orally.
Placebo drug.
Take it once daily for 8 weeks orally.
|
|
Active Comparator: Active Comparator 1
RLD2003
|
Take it once daily for 8 weeks orally.
Placebo drug.
Take it once daily for 8 weeks orally.
|
|
Active Comparator: Active Comparator 2
RLD2004
|
Placebo drug.
Take it once daily for 8 weeks orally.
Take it once daily for 8 weeks orally.
|
|
Active Comparator: Active Comparator 3
RLD2005
|
Placebo drug.
Take it once daily for 8 weeks orally.
Take it once daily for 8 weeks orally.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in sitting systolic blood pressure
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in sitting systolic blood pressure
Time Frame: baseline, 4 weeks
|
baseline, 4 weeks
|
|
Change from baseline in sitting distolic blood pressure
Time Frame: baseline, 4 weeks, 8 weeks
|
baseline, 4 weeks, 8 weeks
|
|
Proportion of subjects achieving blood pressure control
Time Frame: 4 weeks, 8 weeks
|
4 weeks, 8 weeks
|
|
Proportion of responder
Time Frame: baseline, 4 weeks, 8 weeks
|
baseline, 4 weeks, 8 weeks
|
|
Change from baseline in pulse pressure(sitSBP - sitDBP)
Time Frame: baseline, 4 weeks, 8 weeks
|
baseline, 4 weeks, 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Moo-Yong Rhee, M.D., Ph.D., Donggguk University Ilsan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HM-APOLLO-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.